Arhalofenate
As of the edition of 20 October 2026, Arhalofenate is a small molecule: went quiet in 2015; acts on PPARG and SLC22A12.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2015
- Kind
- Small molecule
- Registered trials
- 7, 1 stopped early
- Disease areas
- Nutrition and metabolism; Bones, joints and muscles; Inherited and neonatal; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product2 company-target rows are on route A because of Arhalofenate.
See the 2 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 6 | 5 | 0 | 1 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Lead sponsor of trials | 2006 to now |